Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tripartite motif-containing protein 21 (TRIM21) is a multifunctional cytosolic E3 ubiquitin ligase and a high-affinity intracellular Fc receptor for IgG, IgM, and IgA [1, 2]. It serves as a critical component of the intracellular innate immune system by detecting and neutralizing antibody-coated viruses and bacteria that have escaped extracellular defenses and entered the cytoplasm [2]. Upon binding the Fc region of an antibody, TRIM21 undergoes auto-ubiquitination and recruits the 26S proteasome to rapidly degrade the entire antibody-pathogen complex, a mechanism termed antibody-dependent intracellular neutralization (ADIN) [2, 3]. Additionally, TRIM21 regulates inflammatory signaling by modulating the stability of interferon regulatory factors (IRFs) such as IRF3, IRF5, and IRF7, thereby influencing the production of type I interferons [4]. Clinically, TRIM21 is well-known as the Ro52 autoantigen, with anti-Ro52 antibodies serving as key diagnostic biomarkers for systemic lupus erythematosus and Sjögren's syndrome [1, 5]. In drug development, TRIM21 is the central effector in "Trim-Away" technology, which utilizes exogenous antibodies to trigger the targeted degradation of endogenous proteins, offering a potential therapeutic avenue for diseases driven by "undruggable" proteins [3]. [1] UniProt Consortium. (2023). P19474 (TRIM21_HUMAN). [2] Mallery, D. L., et al. (2010). Antibodies mediate intracellular immunity through tripartite motif-containing protein 21 (TRIM21). PNAS. [3] Clift, D., et al. (2017). A Method for the Acute and Rapid Degradation of Endogenous Proteins. Cell. [4] Espinosa, A., et al. (2009). The Sjögren's syndrome antigen Ro52/TRIM21 regulates T cell function and cytokine production. Journal of Immunology. [5] Schulte-Pelkum, J., et al. (2009). Clinical significance of anti-Ro52 antibodies. Clin Rev Allergy Immunol.
TRIM21 is targeted primarily through the recruitment of its E3 ubiquitin ligase activity to degrade specific proteins via antibody-binding (Trim-Away) or through the modulation of its role in interferon signaling and autoantibody recognition.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tripartite motif-containing protein 21 (TRIM21).